This work reports a novel FeO@polydopamine/Au/polydopamine core/shell nanocomposite toward a magnetically separable nanocatalyst. Because the polydopamine (PDA) layer-sandwiched Au nanocrystals were prepared by a layer-by-layer method, the content of Au could be controlled by varying the Au shell number (such as burger-like FeO@PDA/Au/PDA/Au/PDA). FeO@PDA/Au/PDA exhibited excellent catalytic activity in reducing p-nitrophenol because the substrate could penetrate the PDA shell. Owing to the protection of the PDA shell, FeO@PDA/Au/PDA presented higher cyclability than FeO@PDA/Au. The activity of FeO@PDA/Au/PDA maintained 95% after 7 cycles, while that of FeO@PDA/Au was only 61%. The detailed cycling catalytic mechanism was investigated, and it was found that the catalytic rate of FeO@PDA/Au/PDA/Au/PDA was faster than that of FeO@PDA/Au/PDA because of the higher Au content. Interestingly, this method could be extended for other magnetic nanocomposites with two different kinds of noble metal nanocrystals integrated within one particle, such as FeO@PDA/Au/PDA/Ag/PDA and FeO@PDA/Au/PDA/Pd/PDA.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.langmuir.8b00302 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biomarkers.
Alzheimers Dement
December 2024
Michigan Alzheimer's Disease Research Center, Ann Arbor, MI, USA.
Background: Diffusion magnetic resonance imaging (dMRI) permits characterizing differences in white matter microstructure associated with amnestic mild cognitive impairment (aMCI) and Alzheimer's dementia (AD). However, most dMRI measures aggregate signals across multiple axonal fiber populations with varying spatial orientations, which limits the sensitivity and specificity of clinical diagnosis. To overcome this shortcoming, we estimated fiber density (FD) measures, independently from crossing fiber populations, and extracellular cerebral spinal fluid (CSF).
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Background: The identification of novel blood-based biomarkers of small vessel disease of the brain (SVD) may improve pathophysiologic understanding and inform the development of new therapeutic strategies for prevention. We evaluated plasma proteomic associations of white matter fractional anisotropy (WMFA), white matter hyperintensity (WMH) volume, enlarged perivascular space (ePVS) volume, and the presence of microbleeds (MB) on brain magnetic resonance imaging (MRI) in the population-based Multi-Ethnic Study of Atherosclerosis (MESA).
Methods: Eligible MESA participants had 2941 plasma proteins measured from stored blood samples (collected in 2016-2018) using the antibody-based Olink proteomics platform, and completed brain MRI scans in 2018-2019.
Biomarkers.
Alzheimers Dement
December 2024
University of Kansas Medical Center, Kansas City, KS, USA.
Background: Cerebral blood flow (CBF) and glucose utilization have both proven sensitive biomarkers of brain function in Alzheimer's disease. However, while blood flow supplies glucose to cells to meet local demand, and therefore, are inter-related, the two aspects are physiologically distinct. Our goal was to conduct a region-to-region correlation of magnetic resonance imaging (MRI) and F-fluorodeoxyglucose positron emission tomography (FDG-PET) biomarkers of cerebral blood flow and glucose utilization to determine whether these physiologically distinct biomarkers yield functionally distinct information.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Background: While magnetic resonance imaging (MRI) markers of neurodegeneration are nonspecific to Alzheimer's disease (AD) pathology, they have been correlated with cognitive dysfunction, and therefore, provide important information pertaining to disease staging. Neurodegeneration in AD is commonly assessed with macrostructural measures of brain atrophy, such as hippocampal volume. However, recent investigations have shown that markers of neural microstructure derived from diffusion MRI (DWI) may provide supplementary insight into the progression of AD pathophysiology.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.
Background: Alpha-synuclein pathology underlies Lewy body diseases and can also occur comorbid to other neurodegenerative pathologies. The lack of an in vivo measure for alpha-synuclein pathology until recently has limited thorough characterization of its brain atrophy pattern, especially during early disease stages. We therefore aimed to assess the association of alpha-synuclein pathology in cerebrospinal fluid (CSF) with magnetic resonance image (MRI) structural measures in three independent cohorts, and separately in clinically unimpaired (CU) and cognitively impaired (CI) individuals, the latter reflecting a memory clinic population.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!